2024
How I treat challenging transfusion cases in sickle cell disease
Chou S, Hendrickson J. How I treat challenging transfusion cases in sickle cell disease. Blood 2024 PMID: 38728382, DOI: 10.1182/blood.2023023648.Peer-Reviewed Original ResearchDelayed hemolytic transfusion reactionSickle cell diseaseRed blood cellsTransfusion of red blood cellsRed blood cell alloantibodiesRed blood cell transfusionCell diseaseHemolytic transfusion reactionsManagement of complicationsAlloimmunized patientsRh alloimmunizationCurative therapyTransfusion guidelinesTransfusion recipientsClinical dilemmaFuture transfusionsTransfusionPatient populationTransfusion casesTransfusion reactionsBlood donorsRH variantsBlood cellsAlloimmunizationMedicine providersDecreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource
Ito S, Pandya A, Hauser R, Krishnamurti L, Stites E, Tormey C, Krumholz H, Hendrickson J, Goshua G. Decreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource. American Journal Of Hematology 2024, 99: 570-576. PMID: 38279581, DOI: 10.1002/ajh.27211.Peer-Reviewed Original ResearchSickle cell diseaseDelayed hemolytic transfusion reactionQuality-adjusted life expectancyAlloimmunized patientsPatient populationRed blood cell alloimmunizationCell diseaseCost-effective interventionMedical expenditure of patientsHealth system perspectiveExpenditure of patientsIncremental cost-effectiveness ratioHemolytic transfusion reactionsUnited StatesMarkov cohort simulationCost-effectiveAverage patient populationCost-effectiveness ratioBirth cohortAnalytical time horizonAntibody historyCohort simulationTransfusionTransfusion reactionsLife expectancyChapter 7 Consent and an approach to the management of acute and chronic transfusion reactions
Hendrickson J, Lieberman L. Chapter 7 Consent and an approach to the management of acute and chronic transfusion reactions. 2024, 113-124. DOI: 10.1016/b978-0-323-90459-9.00006-2.Peer-Reviewed Original Research
2023
Epidemiological and clinical features, therapeutic strategies and outcomes in patients with hyperhaemolysis: A systematic review
Jacobs J, Stephens L, Allen E, Binns T, Booth G, Hendrickson J, Karafin M, Tormey C, Woo J, Adkins B. Epidemiological and clinical features, therapeutic strategies and outcomes in patients with hyperhaemolysis: A systematic review. British Journal Of Haematology 2023, 201: 1025-1032. PMID: 37074146, DOI: 10.1111/bjh.18825.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSickle cell diseaseHyperhaemolysis syndromeAnti-globulin testRed blood cellsSupportive transfusionsIndirect anti-globulin testDirect anti-globulin testIntravenous immune globulinHaemolytic transfusion reactionsImmune globulinMedian hemoglobinClinical featuresCommon therapyUnderlying pathophysiologyTransfusion reactionsCell diseaseSevere formTherapeutic strategiesPatientsSystematic reviewBlood cellsTransfusionHyperhaemolysisDaysCorticosteroids
2022
Assessment of polymicrobial interactions in bacterial isolates from transfused platelet units associated with sepsis
Kerantzas CA, Merwede J, Snyder EL, Hendrickson JE, Tormey CA, Kazmierczak BI, Peaper DR. Assessment of polymicrobial interactions in bacterial isolates from transfused platelet units associated with sepsis. Transfusion 2022, 62: 2458-2463. PMID: 36178430, PMCID: PMC11472026, DOI: 10.1111/trf.17136.Peer-Reviewed Original ResearchConceptsAcinetobacter calcoaceticus-baumannii complexBlood productsS. saprophyticusPlatelet unitsContaminated blood productsCDC investigationsApheresis platelet productsTransfusion reactionsPolymicrobial contaminationPlatelet productsDisease controlBacterial isolatesStudy designStaphylococcus saprophyticusPolymicrobial interactionsCDC casesSaprophyticusFuture studiesPotential interactionsCommon sourceSepsisIsolatesCasesCoaggregation
2021
Management of hemolytic transfusion reactions
Hendrickson JE, Fasano RM. Management of hemolytic transfusion reactions. Hematology 2021, 2021: 704-709. PMID: 34889404, PMCID: PMC8791106, DOI: 10.1182/hematology.2021000308.Peer-Reviewed Original ResearchConceptsHemolytic transfusion reactionsRBC alloantibodiesSevere DHTRTransfusion reactionsRed blood cell transfusionDisease-specific risk factorsPathway activationMultiple RBC alloantibodiesBlood cell transfusionSymptoms of painStem cell transplantationSafety of transfusionSickle cell diseaseClassic pathway activationAlternative pathway activationTransfusion avoidanceCell transfusionCurative therapyCell transplantationPatient's hemoglobinRisk factorsTransfusion safetyCell diseaseDHTRHgb A
2020
Pediatric Hemovigilance and Adverse Transfusion Reactions
Sostin N, Hendrickson JE. Pediatric Hemovigilance and Adverse Transfusion Reactions. Clinics In Laboratory Medicine 2020, 41: 51-67. PMID: 33494885, DOI: 10.1016/j.cll.2020.10.004.Peer-Reviewed Original ResearchConceptsTransfusion reactionsBronchopulmonary dysplasia/chronic lung diseaseChronic lung diseaseNonhemolytic transfusion reactionsAdverse transfusion reactionsIntraventricular hemorrhagePediatric populationLung diseasePulmonary reactionsAllergic reactionsPreventive strategiesHemovigilance systemMale childrenAdult populationChildrenTransfusionHemorrhageNeonatesPathophysiologyPopulationHemovigilancePediatricsDisease
2019
Recipient factors influencing red blood cell alloimmunization
Hendrickson J. Recipient factors influencing red blood cell alloimmunization. ISBT Science Series 2019, 15: 194-200. DOI: 10.1111/voxs.12485.Peer-Reviewed Original ResearchSickle cell diseaseRBC alloantibodiesMyelodysplastic syndromeRed blood cell alloimmunizationRed blood cell alloantibodiesRBC alloantibody formationReductionist murine modelHaemolytic transfusion reactionsType of inflammationHigh prevalence ratesForms of autoimmunityDetectable alloantibodiesRBC alloimmunizationTransfusion avoidanceTransfusion burdenAlloantibody formationAntigen matchingRecipient factorsAntibody screenPatient populationHaemolytic diseaseRBC exposureRisk factorsTransfusion reactionsMurine modelChapter 65 Transfusion-Associated Circulatory Overload
Gokhale A, Hendrickson J. Chapter 65 Transfusion-Associated Circulatory Overload. 2019, 401-404. DOI: 10.1016/b978-0-12-813726-0.00065-9.Peer-Reviewed Original ResearchTransfusion-associated circulatory overloadCirculatory overloadLonger hospital courseCardiogenic pulmonary edemaTransfusion-related fatalitiesBlood product infusionSecond leading causeCommon transfusion reactionsTransfused volumeDiuretic useHospital coursePulmonary edemaLeading causeTransfusion reactionsBlood productsProduct infusionHigh riskPreventative strategiesPrevention strategiesJudicious usePatientsOverloadMorbidityEdemaInfusion
2018
Chapter 4 Common Significant Non-ABO Antibodies and Blood Group Antigen Alloimmunization
Baine I, Hendrickson J, Tormey C. Chapter 4 Common Significant Non-ABO Antibodies and Blood Group Antigen Alloimmunization. 2018, 25-39. DOI: 10.1016/b978-0-323-54458-0.00004-0.ChaptersNon-ABO antibodiesBlood group antibodiesGroup antibodiesCompatible RBC unitsEnd-organ damageHemolytic transfusion reactionsSetting of pregnancyCommon adverse outcomeFormation of alloantibodiesSickle cell diseaseRBC alloimmunizationPregnant patientsOrgan damageMyelodysplastic syndromePregnant womenAdverse outcomesGeneral patientsTransfusion reactionsHemolytic diseaseCell diseaseHigh riskRed blood cell surfaceImmunologic conceptsClinical practiceAlloimmunization
2017
Interleukin-6 receptor α signaling on CD4+ T cells drives RBC alloantibody generation and T follicular helper cell differentiation in a murine model of RBC alloimmunization.
Arneja A, Salazar J, Jiang W, Hendrickson J, Zimring J, Luckey C. Interleukin-6 receptor α signaling on CD4+ T cells drives RBC alloantibody generation and T follicular helper cell differentiation in a murine model of RBC alloimmunization. The Journal Of Immunology 2017, 198: 201.27-201.27. DOI: 10.4049/jimmunol.198.supp.201.27.Peer-Reviewed Original ResearchRBC alloimmunizationRed blood cellsIL-6RαT cellsAntigen-negative red blood cellsFollicular helper cell differentiationInterleukin-6 receptor αFollicular helper cellsHemolytic transfusion reactionsViable therapeutic optionLife-saving therapySignificant clinical problemSignificant clinical consequencesInterleukin-6 receptorHelper cell differentiationSpecific CD4Multiple alloantibodiesOccasional mortalitySignificant morbidityTherapeutic optionsAvailable biologicsFunctional outcomeHelper cellsTransfusion reactionsClinical consequences
2013
Chapter 63 Transfusion-Associated Circulatory Overload
Hendrickson J, Hillyer C. Chapter 63 Transfusion-Associated Circulatory Overload. 2013, 413-415. DOI: 10.1016/b978-0-12-397164-7.00063-x.Peer-Reviewed Original Research
2010
Use of mouse models to study the mechanisms and consequences of RBC clearance
Hod E, Arinsburg S, Francis R, Hendrickson J, Zimring J, Spitalnik S. Use of mouse models to study the mechanisms and consequences of RBC clearance. Vox Sanguinis 2010, 99: 99-111. PMID: 20345515, PMCID: PMC3580149, DOI: 10.1111/j.1423-0410.2010.01327.x.Peer-Reviewed Original ResearchConceptsMouse modelRBC clearanceImmune globulin therapyAutoimmune haemolytic anaemiaHaemolytic transfusion reactionsGlobulin therapyRBC transfusionTransfusion reactionsHaemolytic anaemiaAnimal modelsTractable animal modelTransfusion medicineCell clearanceClearancePathophysiologyHuman disordersUnanswered questionsTransfusionComplicationsAnemiaImmunomodulationTherapyMiceAntibodies
2009
Leukoreduction Decreases Alloimmunogenicity of Transfused Murine HOD RBCs.
Hendrickson J, Hod E, Spitalnik S, Hillyer C, Zimring J. Leukoreduction Decreases Alloimmunogenicity of Transfused Murine HOD RBCs. Blood 2009, 114: 640. DOI: 10.1182/blood.v114.22.640.640.Peer-Reviewed Original ResearchWhite blood cellsHOD RBCsPost-transfusion survivalCytometric crossmatchingRBC alloimmunizationLeukoreduction filtersHen egg lysozymeRBC antigensFlow cytometryRBC-specific expressionRed blood cell antigensReductionist murine modelHemolytic transfusion reactionsMinority of miceLateral tail veinAntigen hen egg lysozymeBlood cell antigensEffect of leukoreductionResidual white blood cellsPropridium iodideAltered clearanceHLA alloimmunizationSingle transfusionHLA antigensTransfusion reactionsChapter 42 Neonatal and Pediatric Transfusion Medicine
Hendrickson J, Josephson C. Chapter 42 Neonatal and Pediatric Transfusion Medicine. 2009, 235-239. DOI: 10.1016/b978-0-12-374432-6.00042-7.Peer-Reviewed Original ResearchCardiopulmonary diseaseSevere cardiopulmonary diseaseSmall-volume transfusionsFebrile transfusion reactionsPediatric transfusion medicineHLA alloimmunizationSymptomatic anemiaMajor surgeryPediatric patientsPremature infantsCMV transmissionTransfusion therapyNeonatal patientsPhysiologic changesTransfusion reactionsImmune systemNeonatesFetal periodAnticoagulant-preservative solutionInfantsTransfusionRBC productsTransfusion medicineDlPatientsChapter 57 Transfusion Associated Circulatory Overload
Hendrickson J, Hillyer C. Chapter 57 Transfusion Associated Circulatory Overload. 2009, 327-329. DOI: 10.1016/b978-0-12-374432-6.00057-9.Peer-Reviewed Original ResearchTransfusion-associated circulatory overloadCirculatory overloadPositive fluid balanceCardiogenic pulmonary edemaCongestive heart failureOrthopedic surgery patientsCommon transfusion reactionsDiuretic therapyChest tightnessSurgery patientsHeart failureRespiratory distressCardiac dysfunctionPulmonary edemaTransfusion reactionsBlood productsFluid balanceEpidemiologic studiesCardiopulmonary systemTransfusionMain treatmentPatientsRecipientsOverloadOrthopneaChapter 58 Transfusion Related Acute Lung Injury
Hendrickson J, Hillyer C. Chapter 58 Transfusion Related Acute Lung Injury. 2009, 331-334. DOI: 10.1016/b978-0-12-374432-6.00058-0.Peer-Reviewed Original ResearchTransfusion-related acute lung injuryAcute lung injuryLung injuryDiagnosis of TRALIIncidence of TRALIManagement of TRALINon-cardiogenic pulmonary edemaAnti-HLA antibodiesShortness of breathChest X-rayBilateral infiltratesIntravenous steroidsMultiparous womenPulmonary edemaRadiographic findingsClinical syndromeDonor originTransfusion reactionsBlood productsTransfusionMale donorsBlood bankPatientsInjuryAntibodies